Human microbiome plays a major role in modern healthcare, as they allow easy digestion of food, regulation of immune system, and production of vitamins such as Vitamin K, Vitamin B, and Vitamin B12 essential for blood coagulation. Human microbiomes boosts immunity, nutrition, and others.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/182
Increasing prevalence of C. Difficile infection (CDI) is a major factor driving human microbiome market growth. In 2010, the American Society for Microbiology, study of CDI over a 13-year period in Quebec, Canada, reported an increase in incidence from 35.6 cases per 100,000 population in 1991 to 156.3 cases per 100,000 population in 2003. According to study published in Clinical Infectious Disease journal in 2015, about 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI. Moreover, introduction of probiotic may induce change in intestinal microbiota and can stabilize microbial communities, which may prevent gut inflammation, propelling growth of the human microbiome market over the forecast period. For instance, in October 2018, BioGaia subsidiary MetaboGen introduced two new strains Faecalibacterium prausnitzii (DSM 32379) and Desulfovibrio piger (DSM 32187) for safety study. These strains are derived from human gut microbiome.
Increasing prevalence of gastrointestinal disorder and cancer is expected to propel growth of the human microbiome market
Human microbiome boosts immunity, nutrition, and other uses. High incidence of C. difficile infection is expected to propel demand for antibiotics, prebiotics, and probiotics, which in turn is expected to drive the market growth. According to the Centers for Disease Control and Prevention in 2015, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the U.S., affecting over 500,000 people and causing about 29,000 deaths each year. According to a study published in the Clinical Infectious Disease Journal in 2015, about 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI.
Similarly, according to International Agency for Research on Cancer September 2018 estimates, around 9.6 million death and 18.1 million new cases of cancer will be diagnosed in 2018.
Furthermore, introduction of probiotic may induce change in intestinal microbiota and can stabilize microbial communities, which may prevent gut inflammation, propelling growth of the human microbiome market during the forecast period. For instance, in February 2018, Dannon expanded its Activia range with the introduction of a range of low-fat yogurt drinks, Activia Dailies, in the U.S. Activia Dailies contain live and active probiotics.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/182
Major players operating in the global human microbiome market include, Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synthetic Biologics, Inc., MicroBiome Therapeutics LLC, Vedanta BioSciences, Osel, Inc., and Merck & Co., Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Subscribe to our newsletter to get notification about new updates,information, discount, etc..